Gentamicin + narrow spectrum betalactam
ApprovedSmall molecule
Gentamicin + narrow spectrum betalactam is one of 26 small molecule programs targeting Sepsis. It is currently in Approved.
1
Indications
1
Total Trials
1
Active Trials
25
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
308 competitors in Sepsis
#DrugCompanyPhaseTrials
1Gentamicin + narrow spectrum betalactam
UUniversity Hospital, Akershus
Approved
Corlanor
AmgenPreclinical
Simdax
Orion Corporation, Orion PharmaPreclinical
Zyvox
PfizerPreclinical
Zemplar
AbbViePreclinical
Brevibloc
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Preclinical
Levophed
GGeneral Hospital of Ningxia Medical University
Preclinical
Jardiance
Boehringer IngelheimPreclinical
Micardis
Boehringer IngelheimPreclinical
Achromycin V
WWyeth-Lederle Vaccines
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- UUniversity Hospital, Akershus